Researchers Present Advances in Prostate Cancer Program
Complete the form below to unlock access to ALL audio articles.
Ciphergen Biosystems, Inc. has announced the discovery of two biomarkers that may aid in the management of prostate cancer, including for the detection, staging, and prediction of recurrence.
These markers, a fragment of protein C inhibitor (PCI) and complement factor 4 (C4a), were identified in two separate studies, a multi-institutional study encompassing over 400 men and a five-year longitudinal study following 104 patients after radical prostatectomy.
These studies demonstrated that PCI provides information useful for the detection and staging of prostate cancer, and the combined use of pre-surgery PCI, PSA, and C4a is predictive of prostate cancer recurrence.
The work was performed by Dr. Daniel Chan and Dr. Zhen Zhang of the Johns Hopkins Medical Institutions as part of our research collaboration.
"We are pleased with the progress of our ongoing collaborative prostate cancer program with Johns Hopkins," said Gail S. Page, President and CEO of Ciphergen.
"These findings address a critical aspect of the management of prostate cancer, as the ability to predict recurrence can help physicians and patients understand better the aggressiveness of disease."
"The discovery of PCI using Ciphergen's technology demonstrates its ability to identify markers directly related to the disease process, since PCI is present in seminal fluid and directly interacts with PSA. Further validation is underway."
